Semi-Annual Changes to the NASDAQ Biotechnology Index Nov 14, 2009
China Sky One Medical, Inc. (Nasdaq: - ), Hi-Tech Pharmacal Co., Inc. (Nasdaq: - ), Poniard Pharmaceuticals, Inc. (Nasdaq: - ), SIGA Technologies, Inc. (Nasdaq: - ), Spectrum Pharmaceuticals, Inc. (Nasdaq: - ), Targacept, Inc. (Nasdaq: - ), Vical Incorporated (Nasdaq: - ), and Vanda Pharmaceuticals Inc. (Nasdaq: - ). All securities are classified according to the Industry Classification Benchmark (ICB) as either biotechnology or pharmaceutical. (Primezone Releases)
Flu vaccine rush puts focus on calls for faster delivery Oct 9, 2009
Vijay Samant, a former vaccine executive with drug giant Merck and now CEO of Vical, a San Diego vaccine company, sees it differently. The H1N1 pandemic has "been a test case, and we've been lucky," he says. (USA Today -- News)
Investors look for stocks that could gain from swine flu Sep 22, 2009
Other smaller firms working on H1N1 vaccines include Novavax and Vical , Kolbert says. If those vaccines pan out, they could be more meaningful than Tamiflu is to Gilead at 5% of revenue, Schwartz says. (USA Today -- Money)
752 County Swine Flu Cases Reported, 14 Fatal Jul 31, 2009
San Diego-Based Vical Ready To Produce Swine Flu Vaccine. SDSU Student Now 'Probable' Swine Flu Victim. (TheSanDiegoChannel.com, CA)
Vical to Present Update On Pandemic Influenza Vaccine Program and Overview of Pivotal Phase 3 Melanoma Trial At ASGT Conference May 27, 2009
Press Release Source: Vical Incorporated ... SAN DIEGO, May 27, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (NasdaqGM: - ) today announced that the company will be presenting at a series of upcoming conferences ... Vical's Executive Vice President of Product Development, Alain P. Rolland, Pharm. (Primezone Releases)
Vical Receives Additional Commitment in Registered Direct Offering May 26, 2009
Press Release Source: Vical Incorporated ... SAN DIEGO, May 26, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (NasdaqGM: - ) today announced that it has received a commitment from an additional institutional investor, Special Situations Funds, to purchase approximately $4 ... Under the terms of a Securities Purchase Agreement, Vical will sell to the additional investor an aggregate of 2,000,000 shares of its common stock and options to purchase up to 1,000,000 additional shares of its common... (Primezone Releases)
Vical Advances H1N1 Pandemic Influenza (Swine Flu) Vaccine May 21, 2009
Press Release Source: Vical Incorporated ... SAN DIEGO, May 21, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (NasdaqGM: - ) announced today that in the two weeks since launching its program to develop a vaccine against H1N1 influenza (swine flu), the company has completed development of a prototype H1 vaccine, produced an initial supply of research-grade material, and initiated immunogenicity testing in animals ... Vical and the NMRC are actively pursuing funding to support the program. (Primezone Releases)
Common Virus May Cause High Blood Pressure May 16, 2009
There is no vaccine now, but several companies, including Sanofi-Aventis, Novartis, GlaxoSmithKline PLC and Vical, are working on them. And Swiss drugmaker Roche Holding AG makes an antiviral drug called Valcyte to prevent CMV infections in transplant recipients. (Newsmax)
Vical Updates Lead Vaccine Programs At NFID Vaccine Research Conference and Addresses Potential Response to H1N1 Swine Influenza Outbreak Apr 28, 2009
Press Release Source: Vical Incorporated ... BALTIMORE, April 28, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (NasdaqGM: - ) today announced that the company's Vice President of Vaccine Research, Larry R. Smith, Ph ... Vical's technology could produce a vaccine within six to nine weeks after the H1 hemagglutinin gene is sequenced. (Primezone Releases)
Vical's Vaxfectin(r) Adjuvant Named One of 100 Great Investigational Drugs in Eighth Annual Ranking by Editors of R&D Directions Apr 9, 2009
Vical's Vaxfectin(r) Adjuvant Named One of 100 Great Investigational Drugs in Eighth Annual Ranking by Editors of Rctions - Yahoo ... Press Release Source: Vical Incorporated ... Vical's Vaxfectin(r) Adjuvant Named One of 100 Great Investigational Drugs in Eighth Annual Ranking by Editors of Rctions. (Primezone Releases)
Vical Presents Pandemic Influenza Vaccine Results and Outlook At WHO Meeting Feb 13, 2009
Source: Vical Incorporated ... GENEVA, Feb. 13, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (NasdaqGM: - ) today presented to the world's leading pandemic influenza vaccine experts a summary of complete results from the company's successful Phase 1 trial and future goals for its pandemic influenza DNA vaccine program ... D., Vical's Vice President of Vaccine Research, presented the results and outlook at the invitation-only 5th WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines... (Primezone Releases)
Vical Receives $2.3 Million Payment for Continued Funding of Allovectin-7(r) Phase 3 Trial Feb 11, 2009
Source: Vical Incorporated ... SAN DIEGO, Feb. 11, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (NasdaqGM: - ) today announced the receipt of a $2 ... Through a series of cash payments and equity investments under a previously announced collaborative agreement, Vical has received $17. (Primezone Releases)
Vical Announces News Release and Conference Call Schedule for 2008 Financial Results Feb 10, 2009
Source: Vical Incorporated ... SAN DIEGO, Feb. 10, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (NasdaqGM: - ) today announced that the company will report financial results for the three months and twelve months ended December 31, 2008, before the opening of trading on Tuesday, February 17, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Tuesday, February 17 ... For further information, contact Vical's Investor... (Primezone Releases)
